Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
721 to 740 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. | Nat Med | 2023 | 36914893 | PubTator, text mining | PubMed |
| Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. | J Immunother Cancer | 2023 | 36914208 | PubTator, text mining | PubMed |
| Metabolic Challenges in Anticancer CD8 T Cell Functions. | Immune Netw | 2023 | 36911801 | PubTator, text mining | PubMed |
| "Cold" colorectal cancer faces a bottleneck in immunotherapy. | World J Gastrointest Oncol | 2023 | 36908324 | PubTator, text mining | PubMed |
| Role of ferroptosis in colorectal cancer. | World J Gastrointest Oncol | 2023 | 36908317 | PubTator, text mining | PubMed |
| Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. | Cell Rep | 2023 | 36906850 | PubTator, text mining | PubMed |
| Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target. | Int J Mol Sci | 2023 | 36902091 | PubTator, text mining | PubMed |
| Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy. | Int J Mol Sci | 2023 | 36901782 | PubTator, text mining | PubMed |
| Immunotargeting of Cancer Stem Cells. | Cancers (Basel) | 2023 | 36900399 | PubTator, text mining | PubMed |
| The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. | Cancers (Basel) | 2023 | 36900394 | PubTator, text mining | PubMed |
| CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. | Cancers (Basel) | 2023 | 36900205 | PubTator, text mining | PubMed |
| Challenges of Anti-Mesothelin CAR-T-Cell Therapy. | Cancers (Basel) | 2023 | 36900151 | PubTator, text mining | PubMed |
| CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. | Front Immunol | 2023 | 36891310 | PubTator, text mining | PubMed |
| Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. | Clin Transl Immunology | 2023 | 36890859 | PubTator, text mining | PubMed |
| Co-opting signalling molecules enables logic-gated control of CAR T cells. | Nature | 2023 | 36890224 | PubTator, text mining | PubMed |
| Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. | Cell Res | 2023 | 36882513 | PubTator, text mining | PubMed |
| Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. | J Clin Oncol | 2023 | 36881785 | PubTator, text mining | PubMed |
| Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors. | Oncoimmunology | 2023 | 36875551 | PubTator, text mining | PubMed |
| Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL. | Oncoimmunology | 2023 | 36875548 | PubTator, text mining | PubMed |
| T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. | Front Immunol | 2023 | 36875091 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=37